[Skip to Navigation]
Sign In
Comment & Response
April 2, 2020

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer

Author Affiliations
  • 1The Medical Department, 3D Medicines Inc, Shanghai, China
  • 2State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
JAMA Oncol. 2020;6(6):932. doi:10.1001/jamaoncol.2020.0283

To the Editor In a recent cohort biomarker study, Tie and colleagues1 demonstrated the prognostic value of circulating tumor DNA (ctDNA) analysis after either surgery or adjuvant chemotherapy in stage III colon cancer. We agree with and value the identification of longitudinal noninvasive markers of recurrence risk in patients with cancer; however, we would like to highlight additional aspects that should not be neglected in the study.

Add or change institution